Wegovy gets FDA approval to treat liver condition
The condition MASH (Metabolic Dysfunction-Associated Steatohepatitis) is common and serious.
The weight-loss drug Wegovy just got FDA approval to treat a common and serious liver condition known as MASH (Metabolic Dysfunction-Associated Steatohepatitis), adding to a long list of benefits associated with GLP-1 medications.
Wegovy, the once-weekly injection, was being studied for the treatment of fatty liver disease when it got the green light ahead of schedule.
Dr. Maria Asnis, who runs Stamford Health’s Center for Weight Management, says patients on GLP-1 medications have finally been able to lose their excess weight and reverse their Type 2 Diabetes. She also says there’s a steady stream of promising data.
"The applications and the benefits really go beyond weight," she said. "We’re seeing reduction of risk of cardiovascular disease including heart attack and stroke, resolution of things like sleep apnea, and in this study that had Wegovy approved for MASH."
